S&P Futures
3,769.00 -34.25 (-0.90%) Dow Futures
30,091.00 -274.00 (-0.90%) Nasdaq Futures
11,536.00 -104.75 (-0.90%) Russell 2000 Futures
1,758.50 -23.00 (-1.29%) Crude Oil
86.21 -0.31 (-0.36%) Gold
1,718.60 -11.90 (-0.69%)
Seagen Inc. (SGEN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 137.70 |
| Open | 138.53 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 137.75 - 139.96 |
| 52 Week Range | 105.43 - 192.79 |
| Volume | |
| Avg. Volume | 1,066,043 |
| Market Cap | 25.506B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.78 |
| Earnings Date | Oct 26, 2022 - Oct 31, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 185.10 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SGEN
Related Research
- Seagen Inc.Analyst Report: Seagen Inc.Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.RatingFair ValueEconomic Moat6 days agoMorningstar
- Business Wire
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
BOTHELL, Wash. & SHANGHAI & CAMBRIDGE, Mass., September 27, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the
- Business Wire
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
BOTHELL, Wash. & UTRECHT, Netherlands & PHILADELPHIA, September 26, 2022--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an
- Business Wire
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
BOTHELL, Wash., September 19, 2022--Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) seeking accelerated approval for TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with HER2-positive colorectal cancer who have received at least one prior treatment regimen for unresectable or metastatic disease.
